Navigation Links
Vystar® Corporation Secures a $3M Credit Facility to Fund Growth
Date:3/15/2011

ATLANTA, March 15, 2011 /PRNewswire/ -- Vystar® Corporation (OTC Bulletin Board: VYST), the creator of Vytex® Natural Rubber Latex (NRL), a patented, all-natural raw material that significantly reduces antigenic proteins found in natural rubber latex, has secured $3 million in debt financing through Topping Lift Capital LLC.  The use of proceeds from the transaction will be used for inventory and working capital purposes to fund expected Vytex NRL growth in 2011.(Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO)

William R. Doyle, Chairman, President and Chief Executive Officer of Vystar, commented: "We have several agreements in place with latex companies committed to selling products using Vytex NRL, and it is imperative that we have a financing facility available to support expected inventory requirements and working capital needs. The debt facility through Topping Lift Capital will give us the ability to fund expected purchase orders from the agreements that we announced in 2010, and we will continue to announce updates as we move ahead."

Vystar's Chief Financial Officer, Jack Callicutt, stated: "With this new debt facility in place, Vystar is financially well positioned to capitalize on future sales growth opportunities.  We have the strength to build sufficient inventory levels of Vytex NRL to meet future projected demand, and look forward to updating our shareholders as we continue to gain traction from our partners."

About Vystar CorporationBased in Duluth, GA, Vystar ® Corporation (OTC Bulletin Board: VYST) is the exclusive creator of Vytex Natural Rubber Latex (Vytex NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of antigenic proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, balloons, surgical and exam gloves, other medical devices and natural rubber latex foam mattresses, pillows and sponges.  For more information, visit www.vytex.com.

Forward-looking Statements: Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors.  More information about these factors is contained in Vystar's filings with the Securities and Exchange Commission.Contact:The Investor Relations Group11 Stone St. 3rd FloorNew York, NY212-825-3210IR: Adam HoldsworthPR: Laura Colontrelle/Janet VasquezVystar CorporationJack Callicutt, Chief Financial Officer770-965-0383 x23
'/>"/>

SOURCE Vystar Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/28/2016)... (PRWEB) , ... April 29, 2016 , ... Monthly subscription ... products on the market. They recently reviewed the ZEN BOX , the aromatherapy ... are two single essential oils (like lavender or frankincense) and one Zen Blend (like ...
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s ... week. A group of researchers and leaders from Sanford Health were selected to ... and Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award ...
(Date:4/28/2016)... ... 2016 , ... CastCoverz!, America’s #1 trusted brand for cast ... waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! offers ... night, weatherproof and waterproof covers for most orthopedic devices, including but not limited ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... announces today the open availability of a new CDISC standard, Clinical Trial ... registering clinical trials. This innovative standard will make it possible to build ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one of ... leading force in the fight to reduce tobacco use and its deadly toll, ... help reduce tobacco use. The initiative brings together two organizations committed to achieving ...
Breaking Medicine News(10 mins):